Impel Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	4.74	60.65	88.21	7.1	37
Cash & Cash Equivalents	4.74	60.65	88.21	7.1	37
Cash Growth	-94.05%	-31.24%	1143.30%	-80.82%	-
Receivables	6.59	7.44	1.35	0	0
Inventory	6.86	8.43	2.82	0	0
Other Current Assets	5.24	3.28	2.19	1.08	2.52
Total Current Assets	23.43	79.81	94.58	8.17	39.53
Property, Plant & Equipment	7.82	7	3.15	3.7	2.74
Other Long-Term Assets	3.83	1.75	0.19	0.19	0
Total Long-Term Assets	11.65	8.74	3.34	3.89	2.74
Total Assets	35.07	88.55	97.91	12.06	42.27
Accounts Payable	3.73	6.09	6.37	4.31	2.73
Current Debt	112.56	1.54	0	0.42	0
Other Current Liabilities	8.45	14.53	9.59	5.8	5.6
Total Current Liabilities	124.74	22.16	15.95	10.53	8.32
Long-Term Debt	2.24	49.65	29.45	7.99	0
Other Long-Term Liabilities	0	60.9	0	0	0
Total Long-Term Liabilities	2.24	110.54	29.45	7.99	0
Total Liabilities	126.98	132.71	45.4	18.52	8.32
Total Debt	114.8	51.19	29.45	8.41	0
Debt Growth	128.26%	73.81%	250.14%	-	-
Retained Earnings	-372.35	-321.11	-214.8	-138.26	-92.46
Shareholders' Equity	-91.91	-44.16	52.51	-133.5	-91.7
Net Cash / Debt	-110.06	9.47	58.76	-1.32	37
Net Cash / Debt Growth	-	-83.89%	-	-	-
Net Cash Per Share	-4.63	0.40	4.02	-2.59	106.62
Working Capital	-101.32	57.65	78.62	-2.35	31.2
Book Value Per Share	-3.87	-1.88	3.60	-262.45	-264.25

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).